Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Rheumatology"
DOI: 10.1007/s10067-020-05318-7
Abstract: The effects of biologic disease–modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and cancer are largely unknown. We examined overall survival (OS) in patients with RA and solid malignancies receiving bDMARDs. We performed… read more here.
Keywords: significant differences; received bdmards; solid malignancies; disease ... See more keywords
An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of proteome research"
DOI: 10.1021/acs.jproteome.1c00791
Abstract: Targeting histone epigenetic modification is an important strategy for anticancer therapy. Histone deacetylase inhibitors (HDACis) have been clinically approved in the treatment of diverse hematological cancers, but mechanisms of drug resistance and poor therapeutic efficacy… read more here.
Keywords: saha; integrative proteome; strategy; drug ... See more keywords
Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH With HIV-Controlled Disease Treated for Solid Malignancies: A DAT’AIDS Study
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac109
Abstract: Dear Editor, We read with interest Makinson et al.’s work [1], which found that opportunistic infection (OI) incidence rates in people with HIV (PWH) with cancer and controlled disease were similar to the incidence in… read more here.
Keywords: toxoplasmosis; pwh; dat aids; solid malignancies ... See more keywords
Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofad164
Abstract: Abstract Cytomegalovirus (CMV) infection/disease has been repeatedly reported in patients treated with immune-checkpoint inhibitors (ICIs) and most commonly involves patients with relapsed/refractory (R/R) immune-related adverse events (irAEs). In the current study, we present a patient… read more here.
Keywords: checkpoint inhibitors; immune checkpoint; treated immune; patients treated ... See more keywords
AB0239 HOW SOLID MALIGNANCIES ARE DETECTED IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2022-eular.421
Abstract: According to a meta-analysis reported in 20151), among solid malignancies (cancers), only lung cancer was at an increased risk in patients with rheumatoid arthritis (RA) compared with the general population. A Japanese cohort study reported… read more here.
Keywords: rheumatology; japanese patients; patients rheumatoid; rheumatoid arthritis ... See more keywords
Abstract CT235: A phase I/II clinical study of an oncolytic adenovirus expressing the immunostimulatory transgenes TMZ-CD40L and 4-1BBL in advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct235
Abstract: There is a need for therapeutics with novel mechanisms-of-action for patients with advanced solid malignancies. In this first completed part of LOKON002, a phase I/II (NCT03225989) clinical study, the safety and clinical response to LOAd703… read more here.
Keywords: solid malignancies; load703; phase; study ... See more keywords
Veliparib for the treatment of solid malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221073990
Abstract: Objective Veliparib is a poly adenosine diphosphate ribose polymerase (PARP) −1 and −2 inhibitor with chemo-sensitizing and anticancer activities that has shown promising results in early-phase trials. The aim of this comprehensive review is to… read more here.
Keywords: oncology; solid malignancies; treatment solid; veliparib treatment ... See more keywords
A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359231165968
Abstract: Background: Epidermal growth factor receptor (EGFR) is a well-known target for cancer treatment. However, the authorized anti-EGFR monoclonal antibodies generally cause several toxic effects, especially severe cutaneous toxicities as well as infusion reactions, and the… read more here.
Keywords: dose escalation; escalation; patients advanced; advanced solid ... See more keywords
Microbial spectrum and drug resistance profile in solid malignancies in a large tertiary hospital from Palestine
Sign Up to like & getrecommendations! Published in 2022 at "BMC Infectious Diseases"
DOI: 10.1186/s12879-022-07375-6
Abstract: Background Since the available data for bloodstream infections in solid malignancy tumors are somewhat limited in Palestine, prevention of infection before the occurrence, controlling it when it occurs, and implementing stewardship programs are important ways… read more here.
Keywords: palestine; hospital palestine; drug; resistance ... See more keywords
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0665-2
Abstract: BackgroundThe safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies.MethodsMEDI0680 was administered intravenously once every 2 weeks (Q2W) or… read more here.
Keywords: phase; advanced solid; solid malignancies; study ... See more keywords
TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps3156
Abstract: TPS3156 Background: Approximately 7% of advanced solid malignancies have FGFR gene alterations. However, standard treatment for FGFR-altered malignancies has not been established. Moreover, circulating tumor DNA (ctDNA) analysis has a potential to accurately identify FGFR… read more here.
Keywords: fgfr alterations; advanced solid; malignancies fgfr; tas 120 ... See more keywords